A team of scientists has developed a new version of a common antibiotic that may be far more powerful against a dangerous stomach bacterium linked to cancer.
The research, carried out at the Technical University of Munich (TUM) in Germany, shows that a chemically modified drug can be up to 60 times more effective than the standard treatment. The findings were published in the journal Nature Microbiology.
The bacterium at the center of this study is called Helicobacter pylori, often shortened to H. pylori. It is extremely common, infecting about 43% of people worldwide. Many people do not notice any symptoms, but the infection can cause long-term inflammation in the stomach. Over time, this may lead to ulcers and increase the risk of stomach cancer.
For many years, doctors have used antibiotics to treat H. pylori infections. One of the most common drugs is metronidazole. This antibiotic works by creating harmful chemical reactions inside the bacteria, known as oxidative stress. These reactions damage important parts of the bacterial cells, eventually killing them.
However, a growing problem has made treatment more difficult. Many strains of H. pylori are becoming resistant to metronidazole. This means the drug no longer works as well as it used to. As a result, doctors often need to use higher doses or combine several antibiotics, which can increase side effects and make treatment more complicated.
To solve this problem, researchers at TUM took a closer look at how metronidazole works inside the bacteria. The team, led by Professor Stephan A. Sieber, discovered that the drug does more than just cause oxidative stress. It also targets two important protective systems inside H. pylori.
One of these systems helps the bacteria remove harmful molecules produced during oxidative stress. The other system repairs damaged proteins so the bacteria can survive. By attacking both of these systems, the antibiotic makes it much harder for the bacteria to defend itself.
Using this new understanding, the scientists designed slightly modified versions of metronidazole. These new compounds, called ether derivatives, were created to bind more strongly to the bacteria’s protective proteins. This stronger binding means the drug can block the bacteria’s defenses more effectively.
The results were impressive. In laboratory tests, the new drug was up to 60 times more effective than the original antibiotic. It worked not only on standard strains of H. pylori but also on strains that had already become resistant to treatment.
Importantly, the researchers also found that the modified drug did not increase harm to human cells. This suggests that the new compound could be both powerful and safe, although more testing is needed.
The team then tested the drug in mice infected with H. pylori. The results showed that the infection could be completely cleared using a much lower dose than current treatments.
Another encouraging finding was that the mice’s gut microbiome—the community of helpful bacteria in the digestive system—was less disturbed compared to standard antibiotic therapy.
This is important because many antibiotics can harm beneficial bacteria, leading to side effects such as digestive problems. A treatment that targets harmful bacteria more precisely while protecting helpful microbes would be a major improvement.
The researchers believe this discovery could lead to better treatments for H. pylori infections and help reduce the risk of stomach cancer. However, they also stress that more research is needed before the drug can be used in people. Clinical trials will be required to confirm its safety and effectiveness in humans.
From a critical point of view, this study is very promising because it combines detailed understanding of how antibiotics work with practical drug design. The large improvement in effectiveness and the success in animal models are strong signs of potential.
However, results from laboratory and animal studies do not always translate directly to humans. There may be unexpected side effects or differences in how the drug works in the human body.
In summary, this research offers a hopeful new direction in the fight against antibiotic resistance and stomach cancer. By improving an existing drug rather than creating a completely new one, scientists may be able to bring better treatments to patients more quickly.
If future studies confirm these findings, this new antibiotic could represent a major breakthrough in treating one of the world’s most common and dangerous bacterial infections.
If you care about cancer, please read studies that a low-carb diet could increase overall cancer risk, and vitamin D supplements could strongly reduce cancer death.
For more information about health, please see recent studies about how drinking milk affects the risks of heart disease and cancer and results showing higher intake of dairy foods linked to higher prostate cancer risk.
Copyright © 2026 Knowridge Science Report. All rights reserved.
